Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > BUSINESS
BUSINESS
- Espha’s Velcade AG Wins Approval for Mantle Cell Lymphoma
October 31, 2025
- MSD Files for Keytruda Label Expansion in Ovarian Cancer
October 31, 2025
- Astellas Beats H1 Forecast on Strategic Product Growth, Cost Controls
October 31, 2025
- Vyvanse Generics Drag Takeda Earnings; FY2025 Outlook Trimmed
October 31, 2025
- Pfizer Resumes Supply of Smoking Cessation Pill Champix after 4 Years
October 31, 2025
- Ono’s Sales Rise 7% on Overseas Growth of Qinlock, Romvimza
October 31, 2025
- Leqembi’s April-September Sales at 41.1 Billion Yen: Eisai
October 31, 2025
- TMS Founder Sees “Ray of Hope” in Novel Stroke Drug TMS-007
October 31, 2025
- Jardiance Dominates September Detailing Rankings with Five Wins: Intage
October 31, 2025
- MSD Launches 21-Valent Pneumococcal Vaccine Capvaxive in Japan
October 30, 2025
- AbbVie Files Skyrizi for Pediatric Dosage in Japan
October 30, 2025
- LifeScan Japan Taps AI to Fast-Track Sales Force Development, Draws Interest from Pharma
October 29, 2025
- J-TEC, AlliedCel Ink Service Contract for T-Cell Therapy Production
October 29, 2025
- Japan Gives Orphan Tags for Kyowa Kirin’s Gene Therapy, Cuorips’ Cell Sheet
October 29, 2025
- NEC Crafts Data Platform to Advance Personalized Cancer Vaccine Program
October 28, 2025
- Shionogi Sees Flat 1H Results, Gains Domestic Support from Torii
October 28, 2025
- Novo to End Sales of Victoza in Japan, Fourth GLP-1 to Exit Market
October 28, 2025
- Eisai, Biogen Win Conditional Nod for Leqembi in Canada
October 28, 2025
- J&J Files for 4-Week SC Dosing of Rybrevant in Japan
October 28, 2025
- Viatris Begins Japan Enrollment in Global PIII Study for AMI Drug
October 28, 2025
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…